Pharma & Biotech - Page 21

Bristol Myers Squibb (NYSE: BMY) has selected Houston, Texas, as the location for a new multi-modal manufacturing campus representing approximately $2.3 billion in investment. The facility will be built at Generation Park

Bristol Myers Squibb (NYSE: BMY) has announced plans to build a major new manufacturing campus in Houston, Texas, representing a $2.3 billion investment in domestic production capacity. The facility will be located

Health insurers and pharmacy benefit managers are growing increasingly cautious about how the TrumpRx drug pricing programme could reshape the prescription medication landscape for patients. The initiative introduces federal pricing benchmarks that

AstraZeneca and Bristol Myers Squibb have no ongoing discussions about a potential merger, according to a senior source close to the matter cited by Reuters. “There is no deal between AstraZeneca and

Gilead Sciences has reached a significant commercial milestone, with its HIV prevention franchise surpassing $1 billion in quarterly sales for the very first time. The breakthrough was driven by strong performance from

Novo Nordisk’s oral Wegovy treatment continues to post impressive results in 2026, sustaining momentum as the company eyes broader international expansion beyond the United States. Chief Executive Mike Doustdar struck a confident

Alcon (ALC) has released findings from a new survey highlighting a significant disconnect between parental awareness of vision health and actual eye examination rates among teenagers. The survey, conducted by Wakefield Research

Galderma Laboratories has landed a significant blow against Sanofi in an ongoing multi-case advertising dispute over their rival eczema treatments. The BBB National Programs’ National Advertising Division ruled that Sanofi must change

Novo Nordisk has appointed Omnicom as its agency of record for US media buying, bringing an end to a six-year partnership with WPP’s Wavemaker. Omnicom will take over management of Novo Nordisk’s

AbbVie (ABBV) has reclaimed the number one position in pharmaceutical TV advertising after rival Johnson & Johnson (JNJ) briefly overtook it in June’s rankings. Skyrizi’s return to the top was driven by